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Usage of abused drugs is increasing worldwide, and millions
of individuals are reported to be current users of cocaine,
amphetamine-like stimulants, and other new drugs, with
significant impact for human health and social behavior [1].
Benzodiazepines are widely known as anxiolytics, sedative
hypnotics, anticonvulsants, or muscle relaxants [2,3].
Clinical characteristics of benzodiazepines include a wide
safety margin of their therapeutic index and minimal
serious adverse side-effects [4]. The advent of numerous
new psychoactive substances is a challenge for clinical
toxicology and drug testing laboratories [5]. Dominating
groups of these substances reported are synthetic canna-
binoids and cathinones. These substances are known as
“recreational drugs”, “designer drugs”, etc [5].
The determination of various abused drugs is important
in many fields of analytical toxicology, such as forensic
analysis and workspace drug testing [6,7]. A forensic toxi-
cology analytical method must provide rapidity, simplicity,
high reliability, and accuracy for screening drugs and me-
tabolites of toxicological interest in suspected biological
samples [8].
Drug abuse screening has been used with immunoassay
methods for the purpose of cost-effectiveness and rapid
reporting. However, this may no longer be the optimal so-
lution due to insufficient analyte numbers [9].
Gas chromatography mass spectrometry (GC/MS) was
used for determination of various abused drugs in biological
matrixes [10e14]. The GC/MS technique was the most
commonly used technique to separate and determine
abused drugs and their metabolites due to its cost, high
specificity, and sensitivity. However, GC/MS analysis
required a derivatization process to increase the volatility
of many polar analytes and the derivatization step is costly,
time-consuming, and susceptible to errors.
Alternative screening using chromatographic methods
with mass spectrometry detection offers a powerful com-
plement to immunochemical assays in clinical testing and is
often the best method in forensic, clinical toxicology, and
doping control applications [15e17]. There is a preference
for using liquid chromatography (LC) coupled with MS. Re-
ports of screening or detecting abused drugs, benzodiaze-
pines, and new psychoactive substances using LC tandem
mass spectrometry (LCeMS/MS) in multiple reaction moni-
toring (MRM) mode are available [5,9,15,16,18e25], how-
ever, there are still no reported studies concerning
simultaneous identification of multiple abused drugs, ben-
zodiazepines, and new psychoactive substance in urine by
LCeMS/MS.
The aim of this work was to: (1) develop and validate an
LCeMS/MS method that was suitable for simultaneousidentification of abused drugs, benzodiazepines, and new
psychoactive substances in urine; and (2) to apply this
method for the identification of the abused drugs and me-
tabolites from suspected drug abusers.
Methods
Chemicals and reagents
Abused drugs and new psychoactive substances
The standards including amphetamine, methamphetamine,
MDMA, MDEA, MDA, ketamine, norketamine, morphine,
codeine, cocaine, benzoylecgonine, LSD, buprenorphine,
norbuprenorphine, PMA, PMMA, methadone, ketamine, 6-
acetylmorphine, PCP, 2CeB, zolpidem, 5-MeO-DIPT,
mephedrone, methylone, JWH-018, and JWH-250 were
purchased from Cerilliant (Austin, TX, USA). Para-
methoxyethylamphetamine (PMEA), 2CeB, 2CeC, and
2CeI were bought from TRC (Toronto, Canada), while AMT
and 5-MeO-AMT were obtained from Cayman Chemical (Ann
Arbor, MI, USA).
Benzodiazepine drugs and D9-tetrahydrocannabinol
carboxylic acid
Benzodiazepines including alprazolam, bromazepam, clo-
nazepam, 7-amino-clonazepam, diazepam, nordazepam,
flunitrazepam, 7-aminoflunitrazepam, flurazepam, loraze-
pam, lormetazepam, midazolam, oxazepam, temazepam,
triazolam, chlordiazepoxide, clobazepam, estazolam,
nitrazepam, 7-aminonitrazepam, prazepam, and tetrahy-
drocannabinol carboxylic acid (THCA) metabolite were
purchased from Cerilliant. Nimetazepam and 7-
aminonimetazeapm were kindly obtained from the Taiwan
Food Drug Agency (TFDA). Alpha-hydroxytriazolam was
purchased from Sigma-Aldrich (St. Louis, MO, USA).
High-performance liquid chromatography grade aceto-
nitrile was purchased from Fisher Scientific (Loughborough,
UK), and methanol was purchased from Merck (Darmstadt,
Germany). Reagent grade formic acid was purchased from
J.T. Baker (Center Valley, PA, USA), and the purified water
system (Milli-Q) was from Millipore (Molsheim, France).
Preparation of standard solutions
Preparation of calibration curve and quality control
solution
Abused drug standards or powder were diluted or dissolved
to 500 ng/mL with methanol to obtain a stock solution.
Calibration standards containing mixtures at 12 serial con-
centrations ranging from 0.125 ng/mL to 200 ng/mL were
prepared daily for each analytical batch. These standards
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drug calibration curves and quality control samples were
prepared together with urine samples. The twelve serial
concentrations of standard were 0 ng/mL, 0.125 ng/mL,
0.25 ng/mL, 0.5 ng/mL, 1.0 ng/mL, 2.0 ng/mL, 5.0 ng/mL,
10 ng/mL, 25 ng/mL, 50 ng/mL, 100 ng/mL, and 200 ng/mL.
Enzyme immunoassay
All urine samples were screened by enzyme immunoassay
(EIA) for benzodiazepines (CEDIA) and opiates [DRI; both
CEDIA and DRI reagents were from Microgenics (Fremont,
CA, USA)] using a Hitachi 7170 chemistry analyzer (Diamond
Diagnostics, Holliston, MA, USA). The urine screen cutoff
levels were 200 ng/mL and 300 ng/mL for benzodiazepines
and opiates, respectively.
LC tandem mass analysis
We used an Applied Biosystems API 4000Qtrap triple quad-
rupole tandem mass spectrometer (Applied Biosystem MDS
SCIEX, Concord, Canada) to identify multiple abused drugs,
benzodiazepines, and new psychoactive substances. We
also used Agilent 1200 high performance liquid chroma-
tography (Agilent, Pal Alto, CA, USA). The tandem mass
spectrometer used an electrospray ionization source in a
positive ion mode. The chromatogram was separated using
an ACE5 C18 column (250 mm  4.6 mm i.d., 5 mm). At room
temperature, mobile phase Solvent A consisted of 5%
acetonitrile with 0.1% formic acid, and Solvent B was 95%
acetonitrile with 0.1% formic acid. The chromatography
system was operated in a gradient mode (Table 1). Mass
spectrometric data were collected in a scheduled MRM
model. Data acquisition and quantitative processing were
accomplished using Analyst (1.4.2) software (Applied
Biosystems).
Urine samples were stored at 20C until analysis. To 1-
mL-urine samples in Greiner tubes, we added 0.5 mL 1.5M
sodium bicarbonate buffer (pH 9.5) and 3 mL ethylacetate
for liquideliquid extraction. Each sample was mixed on a
suspension mixer for 30 minutes. After centrifugation for
3 minutes at 2330g, the supernatants were decanted, and
then dried under nitrogen gas. The residues were than
redissolved in 0.5 mL of Solvent A. The mixture was vortex-
mixed for 10 seconds, and filtered through a 0.22-mmTable 1 Time program for the chromatographic separa-
tion procedure.
Total time
(min)
Flow rate
(mL/min)
Mobile phase
Solvent A (%) Solvent B (%)
0 0.0 800 100 0
1 1.0 800 100 0
2 5.0 800 0 100
3 17.0 800 0 100
4 17.1 800 100 0
5 20.0 800 100 0
Solvent A: 5% acetonitrile with 0.1% formic acid.
Solvent B: 95% acetonitrile with 0.1% formic acid.polyvinylidene difluoride filter into a small volume auto-
sampler vial. Then, 50 mL was injected into the LCeMS/MS
system. All control and fortified samples were prepared in
the same manner.Urine samples
During the period of September 2012 to August 2013, a total
of 1091 anonymous decoded urine samples from suspected
drug abusers, who were arrested or inspected by
policeman, was sent to us from 13 drug abuse laboratories
certified by the Department of Health and Welfare in
Taiwan. Urine samples were collected systemically and
randomly with No. 11 and 61 for every 100 residual samples
in those certified laboratories. Urine samples were stored
< 20C until analysis.
To understand the characteristics of the urine samples,
questionnaires concerning sample collection time, age,
sex, education levels, occupation, place of arrest or in-
spection (at party, road, hotel, pub, etc.), and method of
arrest or inspection (road check, pulled over, case investi-
gation, etc.) were completed by the policeman that
arrested the suspected drug abuser. There were in total 769
effective urine samples left with complete questionnaires.
All of the 769 urine samples were analyzed by LCeMS/
MS. Any drug or its metabolite identified in the sample was
interpreted as positive if the levels were above the limit of
quantitation (LOQ).Matrix effect
For 56 drug standards of 0 ng/mL, 1.0 ng/mL, 2.0 ng/mL,
5.0 ng/mL, 10 ng/mL, 20 ng/mL, 50 ng/mL, 100 ng/mL, and
200 ng/mL concentration, we compared standard calibra-
tion curve (SCC) and matrix matched calibration curve
(MCC), and then calculated the matrix effect according to
the formula (MCC slope e SCC slope)/SC slope  100%.Data analysis and statistics
For quantification, peak areas of the native and labeled
transition ions were determined, and the ratios were
evaluated relative to the appropriate standard curve. All
the data in this study were analyzed using Microsoft Excel
2007 (Microsoft, Redmond, WA, USA).Results
MRM chromatograms
Figure 1 shows LCeMS/MS total ion chromatograms of a
spiked urine sample (100 ng/mL) for each analyte by the
order of retention time. The MRM transitions, the declus-
tering potential, the collision energy, and the collision cell
exit potential for the measurements of multiple drugs are
shown in Table 2.
Figure 1. Multiple reaction monitoring (MRM) chromatograms of a spiked urine sample (100 ng/mL standard for each analyte) by
the order of retention time. 1. AMT (6.83), 2. Morphine (6.98), 3. 7-aminonitrazepam (7.16), 4. Codeine (7.20), 5. Methylone (7.29),
6. 6-MAM (7.29), 7. 2C-B (7.33), 8. MDA (7.34), 9. Amphetamine (7.34), 10. Norbuprenorphine (7.35), 11. PMA (7.35), 12. Nor-
ketamine (7.38), 13. 5-MeO-AMT (7.38), 14. MDMA (7.38), 15. PMMA (7.38), 16. Mephedrone (7.38), 17. Methamphetamine (7.40),
18. MDEA (7.41), 19. Ketamine (7.41), 20. 2C-C (7.41), 21. PMEA (7.41), 22. 7-aminonimetazepam (7.43), 23. LSD (7.45), 24. 2C-I
(7.45), 25. Zolpidem (7.46), 26. Chlordiazepoxide (7.46), 27. BZE (7.48), 28. Cocaine (7.48), 29. 7-aminoclonazepam (7.49), 30. 5-
MeO-DIPT (7.51), 31. Flurazepam (7.60), 32. Midazolam (7.61), 33. 7-aminoflunitrazepam (7.66), 34. PCP (7.67), 35. Buprenorphine
(7.68), 36. Methadone (8.06), 37. Bromazepam (8.19), 38. a-hydroxytriazolam (8.35), 39. Nitrazepam (8.58), 40. Oxazepam (8.60),
41. Lorazepam (8.61), 42. Clonazepam (8.66), 43. Estazolam (8.69), 44. Flunitrazepam (8.89), 45. Nordazepam (8.94), 46.
Nimetazepam (8.96), 47. Triazolam (8.98), 48. Alprazolam (8.98), 49. Temazepam (9.07), 50. Clobazam (9.08), 51. Lormetazepam
(9.14), 52. JWH-250 (9.16), 53. Diazepam (9.58), 54. Prazepam (10.30), 55. THCA (10.72), 56. JWH-018 (11.94).
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The accuracy, precision, and recovery of LCeMS/MS anal-
ysis are presented in Table 3. Intraday precision of the
proposed method was evaluated by analyzing, in triplicate,
a spiked quality control urine sample at one of four
different levels (5 ng/mL, 50 ng/mL, 100 ng/mL, or 200 ng/
mL) in the same day. Interday precision was evaluated by
analyzing triplicates of a sample on each of three different
days within a 3-day period. The accuracy, precision, and
recovery of LCeMS/MS analysis are shown in Table 3. The
within-day and between-day precision results of different
control levels were all  15.4% and  18.7%, respectively.
The within-day accuracy ranged from 85.9% to 121.0% and
the between-day accuracy ranged from 66.1% to 128.7%.
For the recovery study, the specimens were spiked with
analytes in urine before and after extraction as describedpreviously [21]. The recovery study ranged from 72.7% to
125.2%. All the data for correlation coefficients (r2), except
for THCA (0.9756), were > 0.9902.
The linearity of the method was investigated by calcu-
lating the regression line with the method of least squares
and expressed by the r2 value. The linearity of multiple
analytes was determined with 11 concentrations as
described [21]. The upper limits of quantification for these
multiple drugs ranged from 5 ng/mL to 200 ng/mL. The
sensitivity of the method was evaluated by determining the
limits of detection (LOD) and LOQ as described previously
[21]. The LOD, LOQ, and linear range conditions are shown
in Table 4. The LOD range was 0.1e15.6 ng/mL, while the
LOQ range was 0.5e31.3 ng/mL, and linearity ranged from
0.5 ng/mL to 200 ng/mL.
Table 5 shows the results of matrix effect evaluation for
multiple abused drugs. Our matrix effect data ranged from
Table 2 Multiple reaction monitoring (MRM) transitions and conditions for analytes.
Compound RT
(min)
Q1 mass
(amu)
Q3 masses
(amu)
DP
(V)
CE
(V)
CXP
(V)
AMT 6.83 131.1 89.1, 55.0 61 21, 31 14, 8
Morphine 6.98 286.2 165.2, 152.2 110 54, 54 11, 11
7-aminonitrazepam 7.16 252.2 121.1, 94.1 51 39, 59 20, 14
Codeine 7.2 300.1 165.1, 115.1 100 63, 105 10, 4
Methylone 7.29 208.2 160.2, 132.1 46 25, 39 26, 22
6-monoacetylmorphine 7.29 328.2 211.1, 165.2 86 45, 55 10, 11
2CeB 7.33 261.0 244.0, 229.0 51 31, 13 10, 26
MDA 7.34 180.0 163.2, 105.1 42 15, 32 9, 8
Amphetamine 7.34 136.2 119.0, 91.1 39 13, 23 6, 3
Norbuprenorphine 7.35 414.2 83.0, 55.2 136 73, 101 12, 6
PMA 7.35 166.1 149.2, 121.1 41 13, 25 26, 20
Norketamine 7.38 224.1 207.1, 125.1 55 18, 32 12, 7
5-MeO-AMT 7.38 205.2 188.2, 147.1 46 13, 29 32, 24
MDMA 7.38 194.2 163.2, 105.2 62 19, 37 10, 8
PMMA 7.38 180.2 149.2, 121.1 46 17, 29 26, 20
Mephedrone 7.38 178.2 160.2, 145.1 51 19, 27 26, 24
Methamphetamine 7.4 150.1 119.1, 91.1 42 16, 26 7, 3
MDEA 7.41 208.2 163.1, 105.1 46 19, 37 28, 16
Ketamine 7.41 238.2 125.1, 220.2 68 38, 22 7, 12
2CeC 7.41 216.1 199.0, 184.0 56 17, 29 34, 30
PMEA 7.41 194.2 149.2, 121.1 51 19, 31 26, 20
7-aminonimetazepam 7.43 266.2 135.1, 77.0 106 39, 89 24, 12
LSD 7.45 323.4 223.1, 281.2 81 33, 25 18, 16
2CeI 7.45 308.0 291.1, 276.0 51 19, 33 14, 46
Zolpidem 7.46 308.2 235.1, 65.1 86 49, 105 36, 8
Chlordiazepoxide 7.46 300.1 283.0, 227.0 81 21, 35 16, 38
BZE 7.48 290.2 168.2, 105.0 84 30, 42 9, 8
Cocaine 7.48 304.3 182.2, 82.1 51 29, 49 32, 12
7-aminoclonazepam 7.49 286.1 121.2, 222.1 91 43, 37 18, 36
5-MeO-DIPT 7.51 275.2 114.2, 174.2 56 23, 29 18, 28
Flurazepam 7.6 388.2 315.0, 317.1 96 35, 27 52, 16
Midazolam 7.61 326.2 291.2, 249.2 101 37, 53 14, 42
7-aminoflunitrazepam 7.66 284.3 135.1, 93.1 86 39, 75 24, 16
PCP 7.67 244.1 86.1, 159.0 50 19, 21 4, 9
Buprenorphine 7.68 468.3 55.2, 84.1 56 97, 77 6, 12
Methadone 8.06 310.2 265.2, 105.0 71 21, 39 16, 6
Bromazepam 8.19 317.2 183.3, 210.2 86 45, 39 30, 34
a-hydroxytriazolam 8.35 360.2 332.0, 240.1 91 41, 63 54, 40
Nitrazepam 8.58 282.1 236.1, 180.1 86 37, 55 40, 30
Oxazepam 8.6 287.0 269.1, 241.1 86 21, 27 44, 20
Lorazepam 8.61 322.0 276.1, 304.1 81 31, 21 14, 16
Clonazepam 8.66 316.1 270.0, 241.2 96 37, 49 44, 40
Estazolam 8.69 295.1 267.2, 205.2 41 33, 55 46, 34
Flunitrazepam 8.89 314.1 239.1, 268.1 66 39, 51 46, 14
Nordiazepam 8.94 271.1 140.1, 77.0 76 41, 89 22, 10
Nimetazepam 8.96 296.1 250.1, 221.1 101 35, 47 14, 16
Triazolam 8.98 344.0 309.0, 316.0 81 39, 41 54, 54
Alprazolam 8.98 309.1 281.1, 205.2 101 39, 61 46, 32
Temazepam 9.07 301.0 255.2, 283.2 86 29, 19 44, 50
Clobazam 9.08 301.1 259.2, 224.3 86 29, 47 44, 38
Lormetazepam 9.14 336.0 290.1, 318.0 71 29, 19 16, 18
JWH-250 9.16 352.2 121.0, 91.0 71 31, 75 20, 12
Diazepam 9.58 285.1 154.1, 193.3 51 39, 45 26, 32
Prazepam 10.30 325.2 271.1, 140.2 86 33, 53 14, 22
THCA 10.72 345.2 327.2, 299.3 106 23, 29 18, 16
JWH-018 11.94 342.2 155.0, 127.2 101 35, 63 26, 55
Bold masses depict quantification transitions.
CE Z collision energy; CXP Z collision cell exit potential; DP Z declustering potential; Q1 Z quadrupole 1; Q3 Z quadrupole 3;
RT Z retention time; THCA Z D9-tetrahydrocannabinol carboxylic acid.
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Table 3 Precision, accuracy, and recovery of liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis.
Compound Precision (%) (n Z 3) Accuracy (%) (n Z 3) Recovery (%)
(n Z 3)Intraday Interday Intraday Interday
Nimetazepam 1.6 7.7 97.3  3.1 97.5  15.1 101.9
7-aminonimetazepam 7.9 6.3 101.9  16.2 92.3  11.6 88.1
Nitrazepam 7.4 6.8 98.0  14.5 111.2  15.0 72.7
Flunitrazepam 6.8 2.3 96.0  13.1 103.2  4.7 98.3
7-aminoflunitrazepam 4.3 8.1 93.3  8.1 106.5  17.3 120.6
Diazepam 4.1 2.9 99.4  8.2 97.8  5.7 95.0
Nordazepam 4.3 3.5 98.6  8.5 94.0  6.6 76.8
Oxazepam 8.1 10.6 93.3  16.0 92.3  19.7 100.4
Lorazepam 6.5 8.1 100.2  13.1 106.2  17.2 89.3
Temazepam 0.8 16.1 98.1  1.5 86.7  27.9 82.8
AMP 5.5 5.1 100.9  11.1 92.3  9.5 116.4
MAMP 9.8 18.2 95.2  10.9 116.7  42.5 97.2
Codeine 11.5 11.8 101.4  23.3 93.8  22.2 100.4
Cocaine 0.8 1.3 98.4  1.5 96.8  2.5 101.4
PCP 2.3 5.0 91.6  4.2 88.5  8.9 84.3
BZE 4.7 4.3 121.0  11.4 108.8  9.5 107.0
Ketamine 1.6 5.1 99.9  3.2 103.8  10.7 95.3
Norketamine 2.9 4.7 101.1  5.7 101.8  10.6 98.6
Morphine 15.4 13.2 87.6  13.7 91.7  24.2 85.8
6MAM 5.4 14.2 91.9  3.2 128.7  36.7 113.5
Methadone 6.7 12.8 87.3  9.7 103.8  26.5 96.9
MDA 4.4 3.4 97.2  8.5 95.3  6.5 101.6
MDMA 2.8 1.6 101.7  5.8 94.2  3.1 95.1
MDEA 2.3 3.2 89.7  4.0 96.5  6.2 99.8
Midazolam 10.2 14.3 99.3  20.3 94.5  27.0 80.6
Zolpidem 2.9 6.0 98.1  5.7 100.7  12.1 97.7
Prazepam 1.3 3.6 96.8  2.5 98.0  7.0 99.5
Triazolam 6.3 6.6 100.1  12.5 104.2  13.9 107.0
Clonazepam 1.9 5.3 93.8  3.5 97.7  10.3 70.3
Clobazam 3.8 6.5 96.1  7.3 101.0  13.1 83.2
Chlordiazepoxide 3.5 3.5 100.8  7.1 92.8  6.5 99.6
Alprazolam 8.3 8.2 100.4  16.6 96.7  15.9 89.0
PMA 3.4 4.6 98.1  6.7 97.7  9.1 108.3
PMMA 2.2 11.1 85.9  3.8 94.5  21.0 95.1
Methylone 6.8 8.6 97.6  13.7 121.1  20.9 107.6
Mephedronea 0.9 5.5 96.8  1.8 98.9  11.0 90.1
JWH-018 4.5 4.2 96.9  1.8 74.3  20.7 81.5
JWH-250 2.3 3.9 109.5  26.1 100.7  7.9 111.0
Bromazepam 11.9 3.3 99.4  17.4 109.0  7.2 103.6
Buprenorphine 8.7 9.3 101.5  25.4 89.2  16.7 113.6
a-hydroxytriazolam 12.5 18.7 98.6  23.9 91.2  34.0 78.9
Lormetazepam 2.5 3.0 102.0  5.0 102.5  6.1 90.3
7-aminonitrazepamb 8.8 5.4 88.5  15.6 93.4  10.1 86.7
5-MeO-AMT 2.3 0.8 95.5  4.4 99.7  1.5 110.9
AMT 4.0 14.2 98.0  4.5 94.4  26.9 77.4
Estazolam 3.8 4.0 100.5  7.5 95.5  7.5 101.4
THCA 5.6 5.8 98.0  4.5 66.1  23.4 81.5
Flurazepam 5.6 4.9 98.0  4.5 97.3  9.6 101.0
Norbuprenorphine 3.5 7.8 98.3  6.9 94.7  13.8 106.6
LSDc 4.6 6.7 104.7  9.6 94.3  12.6 106.2
7-aminoclonazepam 1.4 1.2 92.7  2.5 101.7  2.5 97.4
PMEA 4.5 4.0 97.3  9.6 94.0  7.5 96.9
2CeC 4.6 3.5 95.5  8.7 100.0  7.0 112.4
2CeI 2.4 2.4 96.4  4.6 96.7  4.6 114.9
2CeB 4.6 7.2 99.3  9.1 104.3  15.0 125.2
5-MeO-DIPT 4.0 3.4 110.1  16.8 93.8  6.4 102.9
a Precision concentration: 50 ng/mL.
b Precision concentration: 5 ng/mL.
c Precision concentration: 100 ng/mL. All others are 200 ng/mL.
Table 4 Limits of detection, quantification, and linearity
determined for multiple drugs.
Compound LOD
(ng/mL)
LOQ
(ng/mL)
Linearity
range
(ng/mL)
r2
Nimetazepam 1 5 5e200 0.9930
7-aminonimetazepam 2 10 10e200 0.9968
Nitrazepam 0.5 1 1e200 0.9971
Flunitrazepam 0.5 2 2e200 0.9987
7-aminoflunitrazepam 0.5 5 5e200 0.9926
Diazepam 0.5 1 1e200 0.9965
Nordazepam 0.5 1.0 1e200 0.9980
Oxazepam 0.5 2 5e200 0.9998
Lorazepam 2 5 5e200 0.9994
Temazepam 0.5 1 1e200 0.9988
Amphetamine 2 5 5e100 0.9976
Methamphetamine 5 10 10e100 0.9972
Codeine 5 10 10e200 0.9971
Cocaine 2 5 5e200 0.9998
PCP 2 5 5e50 0.9928
Benzoylecgonine 0.2 0.5 0.5e5 0.9956
Ketamine 1 5 5e200 0.9969
Norketamine 1 5 5e200 0.9989
Morphine 10 25 25e100 0.9940
6MAM 0.1 0. 5 0.5e10 0.9931
Methadone 1 10 10e100 0.9915
MDA 2 5 5e200 0.9942
MDMA 2 10 10e200 0.9955
MDEA 2 5 5e100 0.9959
Midazolam 0.5 2 2e200 0.9997
Zolpidem 0.5 1 1e200 0.9986
Prazepam 1 2 2e200 0.9970
Triazolam 0.5 2 2e200 0.9975
Clonazepam 0.5 1 1e200 0.9943
Clobazam 0.5 1 5e200 0.9997
Chlordiazepoxide 0.5 1 1e100 0.9999
Alprazolam 0.25 0.5 1e200 0.9967
PMA 2 5 5e100 0.9958
PMMA 2 5 5e100 0.9973
Methylone 1 2 2e25 0.9959
Mephedrone 2 5 10e200 0.9936
JWH-018 15.6 31.3 31.3e200 0.9977
JWH-250 5 10 10e200 0.9951
Bromazepam 2 5 5e100 0.9928
Buprenorphine 2 5 5e200 0.9923
a-hydroxytriazolam 2 5 5e100 0.9917
Lormetazepam 0.25 0.5 0.5e25 0.9902
7-Aminonitrazepam 0.1 0.5 0.5e20 0.9927
5-MeO-AMT 1 2 10e200 0.9971
AMT 2 5 5e50 0.9907
Estazolam 1 2 5e200 0.9938
THCA 7.8 15.6 15.6e125 0.9756
Flurazepam 2 5 5e50 0.9913
Norbuprenorphine 5 10 10e100 0.9943
LSD 5 10 10e100 0.9920
7-aminoclonazepam 2 5 5e100 0.9911
PMEA 2 5 10e100 0.9976
2CeC 0.5 1 10e200 0.9911
2CeI 0.5 1 10e200 0.9968
2CeB 2 5 5e100 0.9938
Table 4 (continued )
Compound LOD
(ng/mL)
LOQ
(ng/mL)
Linearity
range
(ng/mL)
r2
5-MeO-DIPT 2 5 5e25 0.9906
LOD Z limit of detection; LOQ Z limit of quantitation.
124 H.-H. Lee et al.38.95% to 66.0%. Three analytes (MDMA, 7-
aminonitrazepam, and methadone) displayed moderate
suppression effects of 62.27%, e64.99%, and 66.0%,
respectively. In this study, the r2 values of the SCC and MCC
for methadone were 0.8591 and 0.9347, respectively.
Applications of urine samples from suspected drug
abusers
Seven hundred and sixty-nine anonymous decoded human
urine samples were analyzed using the LCeMS/MS and EIA
method. For urine benzodiazepines, when compared be-
tween EIA and LCeMS/MS methods, 213 out of 264 (80.1%)
LCeMS/MS positive samples were negative (false negative)
by EIA. Thirty-eight out of 505 (7.5%) LCeMS/MS negative
samples were positive (false positive) by EIA. Method
comparison between EIA and LCeMS/MS for opiates
[including morphine, codeine, and 6-monoacetyl morphine
(6-MAM)] is presented in Table 6. For those 117 samples
positive by EIA, although without an enzymatic hydrolysis
step to increase free morphine release in our study, there
were still 99, 90, and 50 urine samples positive for
morphine, codeine, and 6-MAM, respectively, by the
LCeMS/MS method.
The five most common identified drugs were ketamine
(37.2%), amphetamine (27.2%), opiates (15.3%), clonaze-
pam (9.4%), and oxazepam (8.3%). New psychoactive sub-
stances 2CeB (7.5%), 2CeC (2.3%), 2CeI (0.9%), PMA (4.6%),
PMMA (3.6%), 5-MeO-AMT (2.0%), methylone (5.2%), meph-
edrone (1.4%), JWH-250 (0.1%), 5-MeO-AMT (2.0%), and 5-
Meo-DIPT (0.1%) were also detected. In this study, overall,
the drug positive rate for one or more drugs in the urine was
79.6% (612/769). The positive rate of combined drugs abuse
was 46.8%.
Discussion
In this study, besides abused drugs and benzodiazepines,
we have developed and validated LCeMS/MS methods for
detecting 11 new psychoactive substances: 2CeB, 2CeC,
2CeI, PMA, PMMA, 5-MeO-AMT, methylone, mephedrone,
JWH-250, 5-MeO-AMT, and 5-Meo-DIPT, suggesting that
these drugs were abused in Taiwan. In Sweden, Al-Saffar
et al. [5] investigated 26 new psychoactive substances, and
found limited influence from urine matrix, linear response
within the measuring range and acceptable imprecision by
using LCeMS/MS. Bell et al. [9] demonstrated a higher
measuring range of new psychoactive substances than that
of Al-Saffar et al. [5].
Our sensitivity of urine benzodiazepines is superior or
equal to the previous results [24,26e28]. Our LOQ of
Table 5 Matrix effect evaluation.
Compound (LR, ng/mL) mSCC r
2 mMCC r
2 Matrix effect (%)
AMT 1.0002 0.9931 0.9343 0.9986 6.57
Morphine 1.0000 0.9919 0.7674 0.9728 23.26
7-aminonitrazepam 1.0495 0.9986 0.3501 0.9924 64.99
Codeine 0.9990 0.9985 0.8333 0.9959 16.67
Methylone 1.0003 0.9892 0.6496 0.9959 35.04
6-MAM 0.9790 0.9815 0.8577 0.9978 14.23
2CeB 0.9998 0.9974 0.4787 0.9533 52.13
MDA 0.9772 0.9925 0.6498 0.9874 35.02
Amphetamine 0.9994 0.9984 0.6090 0.9860 39.10
Norbuprenorphine 0.9774 0.9930 0.4595 0.9976 54.05
PMA 0.9866 0.9918 0.6013 0.9884 39.87
Norketamine 1.0008 0.9937 0.7287 0.9939 27.13
5-MeO-AMT 0.9680 0.9950 0.8284 0.9862 17.16
MDMA 1.0007 0.9928 0.3773 0.9853 62.27
PMMA 0.9610 0.9869 0.4968 0.9858 50.32
Mephedrone 0.9625 0.9848 0.5403 0.9883 45.97
Methamphetamine 0.9660 0.9909 0.4838 0.9922 51.62
MDEA 1.0021 0.9932 0.5039 0.9827 49.61
Ketamine 0.9994 0.9948 0.6919 0.9827 30.81
2CeC 0.9871 0.9947 0.5828 0.9948 41.72
PMEA 0.9894 0.9913 0.4436 0.9981 55.64
7A-nimetazepam 0.9984 0.9939 0.5440 0.9825 45.60
LSD 0.9758 0.9992 0.5515 0.9798 44.85
2CeI 0.9797 0.9932 0.5530 0.9963 44.70
Zolpidem 0.9784 0.9910 0.5569 0.9854 43.10
Chlordiazepoxide 0.9921 0.9985 0.4864 0.9959 51.36
Benzoylecgonine 0.9896 0.9959 0.5533 0.9985 44.67
Cocaine 0.9103 0.9941 0.4266 0.9436 57.34
7-Aminoclonazepam 0.9735 0.9950 0.6281 0.9976 37.19
5-MeO-DIPT 1.0001 0.9867 0.6754 0.8752 32.46
Flurazepam 0.9441 0.9928 0.5501 0.9956 44.99
Midazolam 0.9728 0.9940 0.4060 0.9786 59.40
7A-flunitrazepam 0.9828 0.9967 0.8226 0.9763 17.74
PCP 0.9996 0.9959 0.6184 0.9665 38.16
Buprenorphine 0.9940 0.9849 0.7250 0.9987 27.50
Methadone 0.4188 0.8591 0.3400 0.9347 66.00
Bromazepam 1.0147 0.9838 1.2773 0.9821 þ27.73
a-hydroxytriazolam 0.9996 0.9992 0.9307 0.9825 6.93
Nitrazepam 0.9993 0.9900 0.7629 0.9831 23.71
Oxazepam 0.9986 0.9978 0.8482 0.9964 15.18
Lorazepam 0.9951 0.9928 0.8612 0.9830 13.88
Clonazepam 0.9991 0.9930 0.7699 0.9979 23.01
Estazolam 0.9980 0.9927 0.8864 0.9937 11.36
Flunitrazepam 0.9937 0.9953 0.7742 0.9920 22.58
Nordiazepam 0.9895 0.9980 0.8903 0.9978 10.97
Nimetazepam 0.9783 0.9913 0.8689 0.9968 13.11
Triazolam 0.9984 0.9977 0.9861 0.9909 1.39
Alprazolam 0.9993 0.9959 1.3895 0.9975 þ38.95
Temazepam 0.9981 0.9978 0.7909 0.9981 20.91
Clobazam 1.0002 0.9988 0.6499 0.9999 35.01
Lormetazepam 0.9926 0.9948 0.8789 0.9878 12.11
JWH-250 0.9991 0.9959 0.7701 0.9897 22.99
Diazepam 0.9895 0.9965 0.9232 0.9996 7.68
Prazepam 0.9844 0.9838 0.6016 0.9919 39.84
THCA 0.9957 0.9904 0.9573 0.9823 4.57
JWH-018 N/A N/A N/A N/A N/A
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Table 6 Method comparison between enzyme immunoassay and liquid chromatography tandem mass spectrometry (LCeMS/
MS).
Opiates/Methods LCeMS/MS
Morphine (þ) Morphine () Codeine (þ) Codeine () 6-MAM (þ) 6-MAM ()
EIA (þ) 99 18 90 27 50 67
EIA () 2 650 15 637 19 633
Total 101 668 105 664 69 700
6-MAM Z 6-monoacetylmorphine; EIA Z enzyme immunoassay.
126 H.-H. Lee et al.flunitrazepam (2 ng/mL) was similar to that of a previous
study [27]. Papoutsis et al. [28] reported quantification of
benzodiazepines including flunitrazepam, 7-
aminoflunitrazepam, nimetazepam, and nitrazepam in
blood by the GC/MS method, but their study had a higher
LOQ than ours. Using LC/MS, Karampela et al. [24]
demonstrated 10 benzodiazepine levels that all had
higher LOD and LOQ values than did ours with urine dilu-
tion. Our within-day and between-day precisions for fluni-
trazepam and 7-aminoflunitrazepam showed lower
precision results data than that of Fuh et al. [26]. The ac-
curacy performance in this study for flunitrazepam and 7-
aminoflunitrazepam was also similar to the studies of Fuh
et al. [26].
In the present study, 80.7% of urine samples were posi-
tive for benzodiazepines by LCeMS/MS but negative (false
negative) by the EIA method. These findings did not mean
that there were no benzodiazepines in the urine samples
but suggested that the benzodiazepine levels were lower
than the EIA threshold of 200 ng/mL. The other cause of
false negative results by the EIA method for benzodiaze-
pines was the presence of nimetazepam. Forty-three sam-
ples were identified to have nimetazepam or 7-
aminonimetazepam by our LCeMS/MS method, but nime-
tazepam and its metabolites were not listed in the benzo-
diazepine drugs by the EIA method using CEDIA reagent,
and thus were negative by this EIA method. Negative
LCeMS/MS results but positive EIA results (false positivity
7.5%) in this study were probably due to the development
and determination of only 20 kinds of benzodiazepines by
the LCeMS/MS method.
One challenge in the development of an analytical uri-
nary method is the presence of glucuronide metabolites.
Often, this issue has been approached by applying glucu-
ronide hydrolysis to the sample [23]. We interpreted urine
opiates as positive based on morphine, codeine, or 6-MAM
levels greater than the LOQ in this study. Hegstad et al.
[22] determined urine morphine and THCA levels by using
an enzymatic hydrolysis step and diluting the urine sample
10 times instead of diluting 250 times for the other drug
test. Similar to the work of Quentela et al. [25], because of
the high sensitivity of both methods that allowed detection
of the parent drug and metabolite at very low concentra-
tions for benzodiazepines, and the instability of several
analytes during incubation in the hydrolysis step (mainly
the amino metabolites), we processed the urine samples
without enzymatic hydrolysis.
For THCA, the most commonly abused drug in the
western world, Hegstad et al. [22] operated LCeMS/MS byelectrospray ion negative mode. In our study, by still using
electrospray ion positive mode, urine THCA levels had the
accuracy of 66.1% and an r2 value of 0.9756 for the linearity
range of 15.6e125 ng/mL. In the study of Feng et al. [29],
they demonstrated significant bias (37.1%) for THCA in all
three fortified pools. Hegstad et al. [22] diluted the urine
250 times for the abused drug test for the purpose of
decreasing matrix effect and extending column life time,
but with the LOQ of 20 ng/mL for several urine benzodi-
azepines and with the LOQ of 10 ng/mL for methamphet-
amine in their study, there was the possibility of false
negative results (if the benzodiazepines screen threshold
was 200 ng/mL, methamphetamine screen threshold was
500 ng/mL).
For the matrix effect in our study, three analytes (MDMA,
7-aminonitrazepam, and methadone) had a matrix effect of
suppression > 60%. Feng et al. [29] observed that morphine
and 7-aminoflunitrazepam also had the ion
suppression > 60% and methadone even had the ion
enhancement of 293%. Scheidweiler and Huestis [23] also
reported that 20 synthetic cannabinoids, JWH-18, and JWH-
250 had a matrix effect of 73% to 52%.Conclusion
We have successfully developed, validated, and applied an
LCeMS/MS method that was suitable for the simultaneous
identification of multiple target analytes including abused
drugs, benzodiazepines, and new psychoactive substances
in urine samples. With the application of the LCeMS/MS
method to 769 urine samples from suspected drug abusers,
the drug positive identification rate was 78.1%. The three
most commonly identified drugs were ketamine (37.2%),
amphetamine (27.2%), and opiates (15.5%).Acknowledgments
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